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Abstract
Purpose: Recombinant interferon beta (IFN-β) has been used for a treatment ofcancers. However, the efficacy of recombinant IFN-β is limited because of its shorthalf-life and side effects. To overcome these problems, we focused on the efficacy ofcell-based therapy (cell therapy) using IFN-β-producing cells in the treatment ofmelanoma. Methods: IFN-β-producing therapeutic cells were constructed by genetransduction using retrovirus vector. Anti-tumor effects of the cell therapy wereinvestigated by a murine melanoma model. Results: IFN-β cell therapysignificantly suppressed the proliferation of B16 melanoma in vitro and the growthof B16-derived tumor in vivo, accompanied with the activation of natural killer(NK) cells. IFN-β cell therapy did not show any systemic side-effects concerninghepatic dysfunction and bone marrow suppression. Conclusion: IFN-β cell therapycould be a candidate as a novel cancer treatment.
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1. IntroductionInterferon-beta (IFN-β) is a member of the type I familyof interferons, which has various activities such asinhibition of viral replication, activation of immune cellsand regulation of cell cycle.1 Since 1980’s, it has beenreported that interferon has anti-tumor effects, thenapplied to the treatment of cancer.2Type I interferon is known to exert anti-tumor effects byboth direct and indirect pathways.3, 4 In the directpathway, type I interferon binds to the specificinterferon hetero dimer receptor (IFNAR1 and R2)expressed on the surface of tumor cells, and activatescomplicated signal transduction such as JAK-STAT,MAPK/p38 and PI3 kinase cascade for various cellularfunctions including anti-tumor effects.5 In the indirectpathway, type I interferon activates many kinds of
immune cells such as macrophages and natural killer(NK) cells,6, 7 which also leads to the anti-tumor effects.IFN-β has been clinically used for the treatment ofseveral types of cancers including melanoma and braintumor.2 In the treatment of melanoma, recombinantIFN-β is subcutaneously administrated into the tumors.However, the repetitive injection of recombinant IFN-βis required to get clinically enough concentration ofIFN-β in patients, because of the short half-life ofinterferon in the tissues. Systemic administration ofrecombinant IFN-β is also performed in the treatment ofbrain tumor8 and hepatitis C virus infection.9 In thesecases, systemic adverse effects such as fever, hepaticdysfunction and bone marrow suppression havepreviously reported and remained serious problems forthe treatment.10
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Cell therapy is one of the unique treatments againstseveral diseases, where cultured-cells such as embryonicfibroblasts are used as therapeutic agents.11, 12 In clinicaluse, inoculation of bone marrow cells has beenperformed as an angiogenic therapy for arteriosclerosisobliterans.13 We have successfully demonstrated theefficacy of the cell therapy using IL-10 producing mouseembryonic cells in murine acute inflammation modelssuch as gout and asthma models, followed by local andcontinuous high concentrated IL-10 production withoutside effects.14, 15 Thus, the cell therapy could be a quitepossible strategy for the treatment of various disorders,such as cancer.In this study, we investigated anti-tumor effects of IFN-βcell therapy in the treatment of melanoma in vitro and in
vivo. As a result, strong anti-tumor effects such asinhibition of cell growth, suppression of tumordevelopment and activation of immune cells includingNK cells and macrophages were observed in both in vitroand in vivo. Our results strongly sugessted that IFN-β celltherapy might be a novel candidate of cancer treatment
via both direct suppression of tumor growth (directpathway) and activation of immune cells (indirectpathway).
2. Methods and Materials
2.1. CellsC57BL/6J-emb (C57) fibroblasts derived from C57BL/6Jmurine embryo and murine melanoma cells (B16) werepurchased from RIKEN Cell Bank (Tsukuba, Japan) andDS Pharma Biomedical (Osaka, Japan), respectively. Cellswere cultured with Dulbecco’s modified Eagle’s medium(DMEM; SIGMA-ALDRICH, St. Louis, MO) supplementedwith 10% fetal bovine serum (FBS; GIBCO by LifeTechnologies, Grand Island, NY), and 100 units/mlpenicillin/100 μg/ml streptomycin (GIBCO) in ahumidified atmosphere of 95% air and 5% CO2 at 37°C.
2.2. MiceSix-week-old male mice on the C57BL/6NJcl backgroundwere purchased from CLEA-Japan (Tokyo, Japan) andwere fed with standard chow pellets and water adlibitum. All animal handlings and procedures wereapproved by the Animal Experimentation and EthicsCommittee of Kitasato University (Approval no. AHS-R14-32, 15-28).
2.3. Construction of therapeutic and control cells
for the therapy
2.3.1. IFN-β gene transduction into murine
fibroblasts using retroviras vectorMurine IFN-β (mIFN-β) gene was artificially synthesizedby Integrated DNA Technologies (Iowa, USA), accordingto the reference sequence from GenBank (Accession No.NM_010510). The synthesized mIFN-β gene was clonedinto ClaI and NotI sites of deficient retrovirus vector,
pDON-5-Neo (Takara, Tokyo, Japan) and transfected topackaging cells, PT67 producing essential proteins forretrovirus components protein such as Gag, Pol and Env(Clontech by Takara, Tokyo, Japan) using EffecteneTransfection Reagent (QIAGEN, Tokyo, Japan), followedby G418 (Roche, Basel, Swizerland) selection. Producedtemporary infectious recombinant retrovirus containingmIFN-β gene was infected to C57 mouse embryonicfibroblast cells (C57), followed by G418 selection anddesignated as therapeutic cells, C57-mIFN-β used for thecell therapy. The pDON-5-Neo was also retrovirallyintroduced to C57 using same procedure thendesignated as C57-EV used as control in the study.Enhanced green fluorescent protein (EGFP) gene wascloned into BamHI and NotI sites of deficient retrovirusvector, pLPCX (Clontech) containing puromycinresistance gene as a selection marker, then transfectedPT67 cells, followed by puromycin (Sigma-Aldrich)selection. Produced temporary recombinant retroviruswas infected to C57-mIFN-β, followed by puromycinselection, then designated as C57-mIFN-β-EGFP.Producing EGFP was verified by fluorescencemicroscope BZ-9000 (Keyence, Osaka, Japan) and usedto evaluate the production of mIFN-β in survivaltherapeutic cells during the therapy.
2.3.2. Expression and production of mIFN-β in
C57-mIFN-βTo validate the mIFN-β gene expression, RT-PCR wascarried out by following method. Total RNA wasextracted from C57-mIFN-β using RNeasy Plus Mini Kit(QIAGEN), and 5 µg of total RNA were used for cDNAsynthesis in a total volume of 50 µl using Omniscript RTKit (QIAGEN). Five out of the 50 µl RT product wassubmitted for PCR in a total volume of 50 µl, followed byin one cycle of initial activation at 94°C for 15 min, 30cycles of denaturation at 94°C for 30 sec, annealing at60°C for 30 sec, and extension at 72°C for 1 min in athermal cycler (GeneAmp PCR System 9700; AppliedBiosystems by Life Technologies). The oligonucleotideprimers used for the PCR are as follows: mIFN-β(forward primer 5’-TCACCTACAGGGCGGACTTCA-3’,reverse primer 5’-AGATCTCTGCTCGGACCACCAT-3’),mGAPDH (forward primer5’-GACGGCCGCATCTTCTTGTG-3’, reverse primer5’-GCCCCGGCCTTCTCCAT-3’). The PCR products wereelectrophoresed with 3% agarose (TaKaRa agarose L03)in TBE buffer. Then the products were stained withGelRed (Wako, Osaka, Japan), and detected with UVtrans illuminator. The concentrations of mIFN-β proteinin over night culture supernatants of C57-mIFN-β cells,tumor tissues, and murine serum were measured bymouse IFN-β ELISA kit (PBL Assay Science), according tothe instruction manual.
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2.4. Anti-tumor effect of mIFN-β secreting
therapeutic cell supernatantTo evaluate the anti-tumor effects of C57-mIFN-β cellson B16 melanoma cells in vitro, 50μl of the over nightcultured supernatant of C57-mIFN-β was added tocultured B16 melanoma cells (3000 cells/ well in 50µlDMEM) then cell growth was evaluated by MTT assay(Roche, Basel, Switzerland) after 48 hours. Thesupernatant of C57-EV was used as control.
2.5. Anti-tumor effects by cell therapy in murine
melanoma model
2.5.1. Murine melanoma model and cell therapyB16 melanoma cells (0.5 × 106 cells/50 µl PBS) wereinoculated into footpad of 6-week-old male C57BL/6NJclmice then C57-mIFN-β cells (0.5 × 106 cells/50 µl PBS)were inoculated as therapeutic cells around theB16-derived tumor after a week of the melanoma cellinoculation. As control, C57-EV were injected instead ofC57-mIFN-β. The size of tumor was daily measured bythe thickness of inoculated footpad in consideration ofuninoculated. For histological assessment of celltherapy, tumor tissues were resected at 7 days after thecell therapy, then embedded by paraffin, followed byhematoxylin-eosin (HE) staining.
2.5.2. Flow cytometry analysis (FCM) of immune
cells induced by the cell therapyInfiltrated immune cells induced by C57-mIFN-β celltherapy were analyzed by FCM. The method of isolationof cells from the tissues was performed basically inaccordance with the previous study.16 The resectedtumor tissues were cut into 3 mm small pieces andfractionated in 2 ml of PBS by scissors. The fractionatedtissues were treated with collagenase D (finalconcentration 2 mg/ml: Roche) for 1 hour at 37°C, thenfiltrated through the 70 µm pore size cell strainer (BD,NJ, USA). Single cell suspension from the tissues waswashed with PBS, and then incubated with 2.4G2 mAb(anti-FcγRIII/II) to block FcγRIII/II receptor mediatednon-specific binding of primary mAb. After washing, thecell suspension was split into two tubes, and eachsamples were stained with mixed antibodies set A and B.The components are follows; set A: FITC conjugatedanti-mouse CD3e , violet fluor 450 conjugatedanti-mouse CD4 , PE conjugated anti-mouse CD8a , andAPC conjugated anti-mouse NK1.1; Set B: FITCconjugated anti-mouse CD11b , APC conjugatedanti-mouse F4/80, and PE conjugated anti-mouseCD45R. Every conjugated antibody was purchased fromBay bioscience (Hyogo, Japan). Stained cells werewashed with FACS buffer, then stained with 7-AAD (BDPharmingen) to distinguish viable and inviable cells. Thecells were applied to FACS Caliber flow cytometer (BDBiosciences). Data were analyzed with FlowJo software(FlowJo, LLC).
2.6. Analysis of therapeutic cell function and side
effects using EGFP-expressing cells
2.6.1. Viability and IFN-β production of
therapeutic cells during the therapyTo assess how the inoculated therapeutic cells work inthe tissues, the viability of the therapeutic cells and theconcentration of mIFN-β in the tissues were evaluated.EGFP-expressing therapeutic cells, C57-mIFN-β-EGFPcells, were inoculated into mouse foot pad (0.5 × 106cells/mouse). The inoculated feet were resected at 14days after the inoculation, then resected tissues wereembedded in parafin and sectioned to 3 μm thickness.To evaluate the viability of the inoculated cells,immunostaining was performed using anti-EGFPantibody (abcam, UK) and VECTASTAIN ABC Rabbit IgGkit (VECTER LABORATORIES). IFN-β production ininoculated and tumor cells, was also evaluated by ELISAmethod.
2.6.2. Evaluation of systemic side effects of cell therapyThe systemic side effects of cell therapy were assessed,by using blood counts and liver enzyme tests. The bloodsamples were harvested from mice at 7 or 14 days afterthe inoculation of C57-mIFN-β-EGFP. Blood counts ofeach blood samples were performed by automatedblood cell counter (MEK-6450, Nihon Kouden, Japan).Liver enzymes, ALT and AST, were evaluated with IDToxALT Colour Endpoint Assay Kit (ID Labs, UK) and IDToxAST Colour Endpoint Assay Kit (ID Labs) according tothe instruction manuals, respectively.
2.7. Statistical analysisData are expressed as the means ± SD or SEM. Statisticalanalysis was performed with the KaleidaGraph software(HULINKS, Tokyo, Japan). The comparison of more thantwo groups was analyzed with one-way ANOVA followedby Turkey’s multiple comparison test. For comparison oftwo groups, Student’s t-test was performed. P < 0.05 wasconsidered statistically significant.
3. Results
3.1. Characterization of C57-mIFN-β used as
therapeutic cells in the therapyThe expression and secreted production of retrovirallyintroduced mIFN-β in C57- mIFN-β and C57-EV wereevaluated by RT-PCR and ELISA, respectively (Figure 1Aand 1B). Resulted 348 bp specific RT-PCR band andapproximate 6600pg/ml of mIFN-B protein weredetected in C57-mIFN-B but undetected in C57-EV.
3.2. Anti-tumor effect of mIFN-β secreting
therapeutic cell supernatantThe culture supernatant of C57-mIFN-β significantlysuppressed the proliferation of B16 melanoma cells in
vitro ,compared to the supernatant of C57-EV or control(mock) (Figure 2). Approximate 50% suppression of theB16 cell growth was observed with supernatant ofC57-mIFN-β.
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Figure 1: Characterization of C57-mIFN-β cells.RT-PCR showed the expression of mIFN-β gene as the specific band of 348bp in C57-mIFN-β cells, but not in C57-EV cells (A).Positive control was mIFN-β DNA cloned in pDON-5-Neo vector, and negative control was PCR mixture without DNAtemplate. The concentration of mIFN-β protein in the supernatant of C57-mIFN-β cells was approximately 6600 pg/ml,whereas not detected (ND) in the supernatant of C57-EV cells (B). Data were shown as mean ± s.d. [n = 3].
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Figure 2: Suppressive effect of secreted mIFN-β from C57-mIFN-β on the proliferation of B16 melanoma cells.The viability of B16 melanoma cells was assessed by MTT assay after the treatment with culture supernatant of C57-mIFN-βcells for 48 hours. The supernatant of C57-mIFN-β cells significantly suppressed the proliferation of B16 melanoma cellscompared with control (without adding supernatant), whereas the supernatant of C57-EV cells did not suppress. Data wereshown as mean ± s.d. [n = 3]. **P < 0.01.
Figure 3: Anti-tumor effects of C57-mIFN-β cells on murine B16-derived melanoma model in vivo.The size of B16-derived melanoma was measured after the inoculation of C57-mIFN-β cells. C57-mIFN-β cell therapysignificantly suppressed the tumor growth compared with the treatment by C57-EV. Tumor size was estimated bysubtraction of the thickness of the normal footpad from the affected footpad. Data were shown as mean ± s.e. [n = 6]. *P <0.05.
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Figure 4: Histological analysis of the cell therapy by C57-mIFN-β cells.The edge area of the resected tumor tissues was stained by HE staining. The right area is covered by B16-derived tumors, andthe circled area is constituted by inoculated C57-mIFN-β cells (A) or C57-EV (B). Between the tumor tissues and C57-mIFN-βcells, there was intense lymphocytic infiltration (arrows). In addition, degeneration of tumor was observed in the tissuetreated by C57-mIFN-β cells (*).
Volume 4 • Number 4 • 2016 International Journal of Cancer Therapy and Oncology 7
www.ijcto.org
© Nakamura et al. ISSN 2330-4049
Figure 5: Flow cytometry analysis of infiltrating immune cell by the cell therapy.The percentage of each lymphocytes content in the infiltrating lymphocyte was investigated by FCM. NK cells, NKT cells andmacrophage contents were significantly increased in the tissues treated with C57-mIFN-β cells. For CD4 T cells and CD8 Tcells, there was no difference C57-EV and C57-mIFN-β. B cells were significantly decreased in the tissues treated withC57-mIFN-β cells. **P < 0.01.
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Figure 6: The viability of C57-mIFN-β-EGFP cells in the tissues.The survival of C57-mIFN-β introduced with EGFP was determined by immunohistochemistry with anti-EGFP antibody (A).At 14 days after the inoculation of C57-mIFN-β-EGFP cells, EGFP-expressing cells were detected as living cells (*). Theconcentration of mIFN-β in the tissues after the injection of cells was assayed by ELISA (B). Approximately 1000 pg mIFN-βwas detected per 1 g of tissue treated with C57-mIFN-β cells , whereas mIFN-β was undetectable (ND) in the tissue inoculatedwith C57-EV cells. Data were shown as mean ± s.e. [n = 3].
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Figure 7: The analysis of side effects by the inoculation of C57-mIFN-EGFP cells.Blood counts including white blood cells (WBC), hemoglobin (Hb) and platelet (Plt) were determined at 7 and 14 days afterthe local inoculation of C57-mIFN-β-EGFP. Every blood counts was not suppressed by the inoculation of C57-mIFN-β cells (A).Liver enzymes including ALT and AST were measured in the serum of mice inoculated with C57-mIFN-β cells. Neither ALTnor AST were elevated by the inoculation of C57-mIFN-β cells (B). Data were shown as mean ± s.e. [n = 3].
3.3. Anti-tumor effects by cell therapy in murine
melanoma model
3.3.1. Suppression of tumor growth by
C57-mIFN-β cell therapyThe tumor size on the mice foot derived from B16 cells,was significantly suppressed by the C57-mIFN-β celltherapy after 7 days of the therapy in comparison withthe C57-EV inoculation (Figure 3). The histologicalanalysis was also carried out using the section from thetumor after 7 days of inoculation with C57-mIFN-β orC57-EV. As shown in Figure 4, there was significantinfiltration of lymphocytes around the B16-derivedtumor tissues after C57-mIFN-β cell therapy, comparedto C57-EV inoculation. The degeneration of tumor cellswas also observed in the marginal area of the tumortissues.
3.3.2. FCM analysis of infiltrated lymphocytesThe component of infiltrated lymphocytes was assessedby FCM. Significant increase of NK, NKT andmacrophages were observed by C57-mIFN-β celltherapy in comparison with C57-EV inoculation and nodifference was observed of CD4+ and CD8+ T cells(Figure 5). Interestingly, B cells were significantlydecreased by the therapy.
3.4. Evaluation of viability, continuous IFN-β
production and side effects using
C57-mIFN-β-EGFPViability, IFN-β production and side effects wereevaluated after 14 days of C57-mIFN-β-EGFP inoculationby immunostaining with anti-EGFP antibody, ELISA andblood test, respectively. Anti-EGFP immunostainingshowed the viability of C57-mIFN-β-EGFP cells at 14
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days after the inoculation (Figure 6A), accompaniedwith continuous hight concentration of mIFN-β(approximate 1000pg/1g tissue, Figure 6B), whereasundetectable amount of mIFN-β protein were observedin C57-EV. The blood sample was simultaneously takenfor mIFN-β ELISA and side effects evaluation. Resultedundetectable amounts of mIFN-β and no significantchange of blood test and liver enzyme value wereobserved (Figure 7).
4. DiscussionOur result indicated mIFN-β cell therapy successfullyshowed anti-tumor effects against melanoma both in
vitro and in vivo. The suppressive effect on melanomacell growth in vitro and melanoma-derived tumordevelopment in vivo might be considered as directanti-tumor effect via IFN-β receptor, followed byactivation of complicated signal transduction includingapoptosis and growth arrest.1, 17 In addition, induction oflymphocytes especially for NK, NKT and macrophagesmight be considered as indirect anti-tumor effect. Thestrong anti-tumor effect of mIFN-β cell therapy might becomposed from those direct and indirect manners,owing to local and continuous high concentration ofmIFN-β production. Interestingly, liposome-mediatedmIFN-β gene therapy also induced NK cell activation butnot for CD4 and CD8.18The mIFN-β cell therapy also showed continuousmIFN-β production after 14 days of the inoculation,without any side effects. The risk for oncogenicity oftherapeutic cells themself still remained for the celltherapy. We have previously tried to use amniotic stemcell MHC double negative. It is, however, introduction oftarget gene still remained problem because of itscharacterization of primary cells. Therefore, recently,ganciclovir induced suicide C57 introduced herpessimplex virus thymidine kinase gene (C57-TK), wasdeveloped as therapeutic cells in our laboratory, andusing C57-TK may avoid the oncogenicity and increasethe safety. We have also observed the inhibition forproliferation of various cancer derive cells such asmurine lung cancer LLC and prostate cancer RM9 (datanot shown). These data suggested the mIFN-β celltherapy may apply for the various cancer treatment.IFN-β is strongly implicated in the regulation ofangiogenesis in various kinds of tumors.19, 20 The tumorangiogenesis is one of the important processes in tumorprogression and metastasis. The cell therapy using ourIFN-β-producing cells could have an ability to inhibittumor angiogenesis, followed by the prevention oftumor metastasis. It has recently reported IFN-βexacerbated CXCL10 production from melanoma andlymphatic endothelial cells.21 CXCL10 is known to playthe suppression of invasiveness and proliferation ofmelanoma,22 therefore the mIFN-β cell therapy isexpected to suppress the metastasis of melanoma via
CXCL10. Dendritic cell-base vaccination has beenstudied in cancer immunotherapy especially in late stagemelanoma.23 Recent study reported that type I IFN alsoplays an important role in dendritic cell vaccines againstmurine melanoma metastasis model.24 Therefore, themIFN-β cell therapy in combination with the dendriticcell vaccination may contribute to improve thetreatment of late stage melanoma.The present study provides important informationregarding the therapeutic potential of geneticallyengineered IFN-β-producing cells in the local tissues oftumors, with minimized systemic side-effects. Takentogether with previous studies, IFN-β is likely to havemultiple anti-tumor effects related to the activation ofimmune cells, regulation of cell cycle andanti-angiogenesis in tumors. Cell-based therapytargeting IFN-β could be a candidate as a novelanti-tumor therapy for the treatment of melanoma aswell as many types of cancers.
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